Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations

Breadcrumb

  1. Emmes Group

Factors that impact on the outcome of second renal transplants in children,

Go back to Resources

Factors that impact on the outcome of second renal transplants in children,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Extension of the Wisconsin Lens Opacity Grading System.

Go back to Resources

Extension of the Wisconsin Lens Opacity Grading System.

Authors:

Location:

Go back to Resources

Excess graft losses in adolescent recipients of living donor (LD) renal transplants (TX): A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Go back to Resources

Excess graft losses in adolescent recipients of living donor (LD) renal transplants (TX): A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Authors:

Location:

Go back to Resources

Evaluation of pre- and post transplant DST/CsA in non-HLA identical living donor kidney transplant recipients.

Go back to Resources

Evaluation of pre- and post transplant DST/CsA in non-HLA identical living donor kidney transplant recipients.

Authors:

Location:

Go back to Resources

Sensitivity with specificity of a screening questionnaire for dry eye,

Go back to Resources

Sensitivity with specificity of a screening questionnaire for dry eye,

Authors:

Go back to Resources

Sample-path insensitivity of symmetric queues in discrete-time.

Go back to Resources

Sample-path insensitivity of symmetric queues in discrete-time.

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Safety profile of Phase I and II preventive HIV tTpe 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group,

Go back to Resources

Safety profile of Phase I and II preventive HIV tTpe 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Safety of kidney biopsy in pediatric transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Go back to Resources

Safety of kidney biopsy in pediatric transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS),

Authors:

Location:

Go back to Resources

Safety and immunogenicity of env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59,

Go back to Resources

Safety and immunogenicity of env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120,

Go back to Resources

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 111
  • Page 112
  • Page 113
  • Page 114
  • Current page 115
  • Page 116
  • Page 117
  • Page 118
  • Page 119
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Contact Us
    • Locations
linkedin X

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions
  • Terms of Use
  • ISO Certification